Form 4: Mirum Pharmaceuticals CFO Reports Stock Transactions
SEC Form 4 Filing
Eric Bjerkholt, CFO of Mirum Pharmaceuticals, reports the disposition of 18,334 common stock shares and the corresponding vesting of restricted stock units on September 11, 2024.
Summary
- On September 11, 2024, Eric Bjerkholt, the Chief Financial Officer of Mirum Pharmaceuticals, reported a transaction involving the company's stock.
- Bjerkholt disposed of 18,334 shares of common stock.
- This transaction was related to the vesting of 18,334 restricted stock units.
- Following the reported transaction, Bjerkholt beneficially owns 32,804 shares of common stock.
- He also holds 36,666 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for publicly traded companies.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key executive, providing transparency.
Key Dates
| Date | Description |
|---|---|
| 09/11/2023 | Start date for the vesting of restricted stock units in three equal annual installments. |
| 09/11/2024 | Date of the reported stock transaction and vesting of restricted stock units. |
| 09/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.